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Abstract
Background: People with depression are usually managed in primary care and antidepressants are often the first-line
treatment, but only one third of patients respond fully to a single antidepressant. This paper describes the protocol for
a randomised controlled trial (MIR) to investigate the extent to which the addition of the antidepressant mirtazapine is
effective in reducing the symptoms of depression compared with placebo in patients who are still depressed after they
have been treated with a selective serotonin reuptake inhibitor (SSRI) or serotonin and noradrenaline reuptake inhibitor
(SNRI) for at least 6 weeks in primary care.
Methods/Design: MIR is a two-parallel group, multi-centre, pragmatic, placebo controlled, randomised trial with
allocation at the level of the individual. Eligible participants are those who: are aged 18 years or older; are currently
taking an SSRI/SNRI antidepressant (for at least 6 weeks at an adequate dose); score ≥14 on the Beck Depression
Inventory (BDI-II); have adhered to their medication; and meet ICD-10 criteria for depression (assessed using the Clinical
Interview Schedule-Revised version).
Participants who give written, informed consent, will be randomised to receive either oral mirtazapine or matched
placebo, starting at 15 mg daily for 2 weeks and increasing to 30 mg daily thereafter, for up to 12 months (to be taken
in addition to their usual antidepressant). Participants, their GPs, and the research team will all be blind to the allocation.
The primary outcome will be depression symptoms at 12 weeks post randomisation, measured as a continuous variable
using the BDI-II.
Secondary outcomes (measured at 12, 24 and 52 weeks) include: response (reduction in depressive symptoms
(BDI-II score) of at least 50 % compared to baseline); remission of depression symptoms (BDI-II <10); change in
anxiety symptoms; adverse effects; quality of life; adherence to antidepressant medication; health and social care
use, time off work and cost-effectiveness. All outcomes will be analysed on an intention-to-treat basis.
A qualitative study will explore patients’ views and experiences of either taking two antidepressants, or an antidepressant
and a placebo; and GPs’ views on prescribing a second antidepressant in this patient group.
Discussion: The MIR trial will provide evidence on the clinical and cost-effectiveness of mirtazapine as an adjunct
to SSRI/SNRI antidepressants for patients in primary care who have not responded to monotherapy.
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Background
Depression is ranked amongst the top five contributors
to the global burden of disease, and by 2030 is predicted
to be the leading cause of disability in high income coun-
tries [1]. People with depression are usually managed in
primary care and antidepressants are usually the first-line
treatment. The number of prescriptions for antidepres-
sants has risen dramatically in recent years; increasing by
7.2 % (3.8 million items) between 2013 and 2014. Indeed,
antidepressants have shown a greater increase in the
volume of prescribing in 2014 than drugs for any other
therapeutic area, with over 57 million prescriptions being
issued in England in 2014, at a cost of £265 million [2].
However, the STAR*D study (Sequenced Treatment
Alternatives to Relieve Depression) found that half of
those treated did not experience at least a 50 % reduc-
tion in depressive symptoms following 12–14 weeks of
treatment with a single antidepressant [3]. The reasons
for this non-response are complex but include what can
be termed treatment-resistant depression (TRD), where an
adequate dose and duration of treatment has been taken.
When first-line antidepressant treatments do not
work, general practitioners (GPs) can be unsure what to
offer next. The National Institute for Health and Care
Excellence (NICE) now advises GPs to reconsider the
treatment option if there has been no response after
4—6 weeks of antidepressant medication [4]. However,
there is currently limited evidence to guide management.
Existing evidence on the pharmacological management
of treatment-resistant depression
The current NICE guideline [4] describes the following
pharmacological strategies for sequencing treatments
after inadequate response to initial treatments: switching
antidepressants; augmenting medication by adding a
drug which is not an antidepressant; and combining
antidepressants. The guidelines comment in general on
the lack of evidence and particularly that ‘the evidence
for the relative advantage of switching either within or
between classes is weak’. Connolly et al. comment that
switching antidepressants after inadequate response is
not ‘unequivocally supported by the data, although
switching from a selective serotonin receptor inhibitor
(SSRI) to venlafaxine or mirtazapine may … offer greater
benefits’ [5]. Similarly, there is very little evidence on
combining two antidepressants.
The evidence for the effectiveness of augmentation
with a non-antidepressant is likewise of variable quality.
There is some evidence for augmentation with lithium
or thyroid hormone, but mainly in combination with tri-
cyclic antidepressants, which are prescribed much less
often today. The use of the atypical antipsychotic drugs
to augment the newer antidepressants is better sup-
ported by research [6, 7], with quetiapine and aripipra-
zole the most promising [8]. However, this combination
has not to date been adopted with any enthusiasm in
UK primary care. This may be because of a lack of ex-
perience in prescribing them for this indication since
they are usually initiated in secondary care, as well as
concerns about their adverse effects [9] (e.g. sedation,
metabolic syndrome and central obesity, extrapyramidal
side effects.) Indeed, the current NICE guidance is that
antidepressants should not be combined or augmented
without the advice of a consultant psychiatrist [4].
It is possible that GPs would consider adding a second
antidepressant, rather than an atypical antipsychotic drug
or lithium, as part of the management of TRD. They are
more familiar with these drugs and their starting routines
and there is less concern about their adverse effects, and
less need for monitoring. In general, stepwise combination
of drug treatments is a standard part of the management
of chronic diseases in primary care such as asthma and
hypertension and has led to improved clinical outcomes.
GPs are comfortable with this model of care and would
probably readily adopt this strategy if it were found to be
effective. We think there may be an opportunity to sub-
stantially improve the treatment of depression in primary
care by using antidepressants in combination. However,
one of the reasons that this strategy has not been adopted
is the lack of convincing evidence for its effectiveness,
especially in the primary care setting.
There is a pharmacological rationale for adding a second
antidepressant to SSRIs or serotonin and noradrenaline
reuptake inhibitors (SNRIs) with a different and comple-
mentary mode of action. Mirtazapine, an alpha2-adre-
noreceptor antagonist, increases central noradrenergic
and serotonergic neurotransmission by inhibiting negative
feedback from synaptic noradrenaline (NA) acting on
presyaptic alpha2-autoreceptors on NAergic neurones and
alpha2-heteroreceptors on 5-hydroxytryptaminergic (5-
HTergic) neurones. Its mechanism of action is, therefore,
different to that of both SSRIs and SNRIs which inhibit
synaptic neurotransmitter reuptake after release. Thus,
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treatment with mirtazapine in combination with either an
SSRI or SNRI may produce a sustained increase in both 5-
HT and NA synaptic availability in terminal fields. A fur-
ther property of mirtazapine not shared by SSRIs and
SNRIs is an affinity for the 5HT-2C receptor where it acts
as an inverse agonist. This mechanism has been linked to
specific therapeutic effects. Overall, there is the poten-
tial for a synergistic action that could enhance clinical
response compared to those patients receiving only
monotherapy. Mirtazapine is now off patent and rela-
tively inexpensive.
Because of its different mechanism of action there is
an argument that switching to mirtazapine alone after
SSRI treatment failure might be an effective strategy,
rather than subjecting patients to the potential adverse
effect burden of a second medication. The STAR*D
study compared mirtazapine to nortriptyline in a group
of patients who had not responded to two consecutive
antidepressant monotherapy regimes. The rates of re-
mission were low for both drugs [10], suggesting that
switching to mirtazapine monotherapy is not the most
useful strategy.
In spite of the potential benefit of combining mirtaza-
pine with an SSRI there is relatively little trial evidence
supporting this strategy. Carpenter et al. compared the
addition of mirtazapine to an SSRI with placebo in a
group of 26 patients who had not responded to at least
4 weeks of monotherapy. Although the sample size was
very small, the results in terms of effectiveness and toler-
ability are encouraging [11] but more definitive evidence
is required before widespread adoption. In patients who
have not failed previous treatment, Blier et al. reported
that mirtazapine in combination with an SSRI gave a
greater improvement than monotherapy [12], and that
it was well-tolerated with either an SSRI or an SNRI
(venlafaxine) [13], with both combinations providing
significantly higher remission rates than an SSRI alone.
In contrast a larger study found no benefit from combining
antidepressants, including mirtazapine and venlafaxine,
over SSRI monotherapy with escitalopram [14], though
combined treatment had a higher side-effect burden.
Mirtazapine treatment is, however, associated with
more weight gain than SSRIs [15] and, therefore, as well
as assessing the efficacy of its combination with SSRIs it
is important to determine its adverse effect burden,
especially in long-term treatment.
Defining treatment-resistant depression (TRD)
Many definitions of treatment resistance have been
proposed. These definitions cover a broad spectrum ran-
ging from failure to respond to at least 4 weeks of anti-
depressant medication given at an adequate dose [16] to
more stringent criteria based on non-response to mul-
tiple courses of treatment [5].
We have used a more inclusive definition of TRD; that
is patients who still meet the International Classification
of Diseases (ICD-10) criteria for depression after taking
an SSRI or SNRI antidepressant at an adequate dose
(based on the British National Formulary (BNF) [17]
and advice from psychopharmacology experts), for a
minimum of 6 weeks. This definition is directly relevant
to UK primary care, given the uncertainty about what
course of action to recommend to this group of patients.
Although this 6-week criterion seems a relatively short
period to define treatment resistance, many of the pa-
tients who satisfy this criterion of ‘non-response’ are suf-
fering from moderate to severe chronic depression. The
baseline measures for a recent study of the effectiveness
of cognitive behavioural therapy (CBT) for treatment-
resistant depression in primary care, the CoBalT study
[18], found that 59 % of those recruited had been de-
pressed for more than 2 years; that 70 % had been pre-
scribed their current antidepressant for more than
12 months; and that 28 % satisfied the ICD-10 criteria
[19] for severe depression. These data on chronicity
and severity illustrate the extent of the unmet need in
this population [20].
At present, there is no good evidence that switching
antidepressants improves outcomes. For this reason the
latest NICE guideline update [21] emphasises considering
alternative strategies, such as augmentation, after a single
failure of antidepressants.
It is, therefore, important to undertake a study to in-
vestigate the effectiveness of the addition of mirtazapine
to SSRIs or SNRIs in primary care. In the UK, most
depression is diagnosed and treated in primary care, and
this is where most antidepressants are prescribed, and
most treatment resistance encountered. The rise in
antidepressant prescribing has continued at a steady rate
in the UK despite the introduction of the government’s
initiative to Improve Access to Psychological Therapies
(IAPT). Failure to adequately respond to treatment is a
substantial problem and there is a need to develop the
evidence base for the rational prescribing of antidepres-
sants in primary care. An effective intervention has the
potential to have a substantial impact on the health and
economic burden associated with this patient group.
Objective
The trial will investigate whether combining mirtazapine
with SNRI or SSRI antidepressants results in better pa-
tient outcomes and more efficient NHS care than SNRI
or SSRI therapy alone in TRD. All patients entering the
trial will be recruited from primary care and will have
treatment-resistant depression, defined as meeting ICD-10
[19] criteria for depression after at least 6 weeks treatment
with either an SSRI or SNRI antidepressant at an
adequate dose.
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Our specific aims are to:
1. Determine the effectiveness of the addition of the
antidepressant mirtazapine to an SSRI or SNRI in
reducing depressive symptoms and improving
quality of life at 12 weeks, 24 weeks and 12 months
(compared to the addition of a placebo)
2. Determine the cost-effectiveness of this intervention
over 12 months
3. Qualitatively (a) explore patients’ views and
experiences of taking either two antidepressant
medications or an antidepressant and a placebo;
(b) identify patients’ reasons for completing or not
completing the study, including withdrawal from
study medication
4. Qualitatively explore GPs’ views on prescribing
combined antidepressant therapy in this
patient group
Methods/Design
Study design
The MIR study is a two-parallel group multi-centre
pragmatic placebo controlled randomised trial with al-
location at the level of the individual. Patients will be
recruited from general practices in England, in the
areas surrounding our four recruiting centres: Bristol,
Exeter, Hull and Keele. The primary outcome will be at
12 weeks. The Beck Depression Inventory (BDI-II) was
selected as the primary outcome, rather than a clinician-
rated instrument, to avoid the potential for observer bias
inherent in using clinician-rated instruments. The double-
blinded randomised allocation will be maintained for a
period of 12 months, although participants can be
unblinded at their request or the request of their GP after
the primary outcome at 12 weeks, and outcomes will also
be measured at 24 weeks and 12 months. These include
cost-effectiveness which will be assessed at 12 months. A
nested qualitative study will explore patients’ and GPs’
views of the use of an additional antidepressant.
Ethical approval was obtained from South East Wales
Research Ethics Committee Panel C (ref: 12/WA/0353);
Bristol Clinical Commissioning Group (CCG), and other
relevant CCGs provided research governance assurance.
Clinical trial authorisation was provided by the Medicines
and Healthcare products Regulatory Agency. The trial
sponsor is the University of Bristol. The trial has been
registered: EudraCT Number: 2012-000090-23 (January
2012); ISRCTN06653773 (September 2012).
Inclusion and exclusion criteria
Inclusion criteria
Primary care patients who: are aged 18 years or older;
have depression treated for at least 6 weeks with any
one of the following SSRI or SNRI antidepressants at
recommended BNF doses: fluoxetine, sertraline, citalo-
pram, escitalopram, fluvoxamine, paroxetine, duloxetine,
or venlafaxine. The minimum SSRI and SNRI dose cri-
teria were based on the BNF and on advice from psycho-
pharmacology experts, and have been used in earlier
trials of TRD [22]. Table 1 lists the adequate dose cri-
teria used in the MIR study. To be eligible, participants
must also have adhered to their medication. While
adherence to medication is difficult to measure, we will
operationalise our definition of treatment resistance by
using the Morisky 4-item self-report measure of compli-
ance [23] as adapted for the CoBalT trial [22]. The
Morisky measure has previously been validated against
electronic monitoring bottles, with a score of zero
(range: 0–4) indicating at least 80 % compliance [24].
Given the relatively long half-life of antidepressant
medication, individuals who have forgotten to take one
or two tablets will not be excluded. Participants also
need to score at least 14 on the BDI-II [25], and have
an ICD-10 diagnosis of depression (assessed using the
Clinical Interview Schedule-Revised version (CIS-R) [26].
Exclusion criteria
GPs will be asked to exclude patients who are: currently
taking combined or augmented antidepressant treatment;
are having their medication managed by a psychiatrist;
have dementia (formal diagnosis), bipolar disorder, psych-
osis or alcohol/substance abuse/dependence; are pregnant,
planning pregnancy, or breast-feeding; are unable to
complete the study questionnaires; have had a previous
adverse reaction to mirtazapine; have current treatment
with a monoamine oxidase (MAO) inhibitor including
moclobemide; or have other medical contraindications
to mirtazapine.
Table 1 Adequate doses for selective serotonin receptor inhibitor
(SSRI) and serotonin and noradrenaline receptor inhibitor (SNRI)
antidepressants – table showing the list of adequate doses of
SSRI/SNRI antidepressants used in the MIR study
Name Trade name Type BNFa Code Minimum adequate
daily dose (mg)
Citalopram Cipramil SSRI 4.3.3 20
Duloxetine Cymbalta/
Yentreve
SNRI 4.3.4 60
Escitalopram Cipralex SSRI 4.3.3 10
Fluoxetine Prozac SSRI 4.3.3 20
Fluvoxamine Faverin SSRI 4.3.3 100
Paroxetine Seroxat SSRI 4.3.3 20
Sertraline Lustral SSRI 4.3.3 100
Venlafazine Effexor SNRI 4.3.4 75
aSource: British National Formulary (BNF) No.55 (March 2008) for BNF code and
dosage. These minimum doses were chosen to reflect prescribing guidance in
UK primary care, and with expert advice from psychopharmacologists
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Recruitment of participants
The trial will recruit participants from primary care who
have depression that has not responded to at least
6 weeks treatment with SSRI or SNRI antidepressants,
prescribed at an adequate therapeutic dose. We plan to
recruit 470 patients over 18 months from 96 practices
linked with our four recruitment centres, using two
methods of recruitment: record search and in-consultation
recruitment.
Method 1: record search
GP practices will search their computerised records for
potentially eligible patients; those who have been pre-
scribed SSRI or SNRI antidepressants for at least 6 weeks
at an adequate dose (Table 1), as recommended in the
BNF [17]. These patients will then be mailed an invitation
by their GP to participate, asking for their permission to
be contacted by the research team. Patients who have not
responded after 2 weeks will be sent one reminder letter
by the practice. GPs will be asked to provide anonymised
data on the age and gender of those patients who were
mailed an invitation to participate (including those who
did not respond) in order to assess the generalisability of
the findings.
Method 2: in consultation
GPs can also identify potentially suitable patients in con-
sultation. They will introduce the trial and ask the pa-
tient for their written consent to be contacted by the
research team.
Postal screening
Patients who have agreed to be contacted by either
method of recruitment will be sent a postal screening
questionnaire. This will contain a BDI-II, a measure of
adherence to antidepressant medication (Morisky), a
question about duration of medicine use, demographic
questions, and a list of the main exclusion criteria. The
GPs will be asked to review all those who appear eligible
on the postal screening, and to confirm that they are
suitable to be prescribed mirtazapine. Once GP approval
is received, patients will be invited to a baseline assess-
ment with a researcher, either in their own home or at
their general practice.
Baseline assessment
The researcher will explain the study in detail and obtain
written informed consent for the baseline assessment. If
the potential participant is agreeable they will complete
the following questionnaires: BDI-II; Morisky (adherence
to medication); Patient Health Questionnaire (PHQ9) [27]
a brief measure of depression; CIS-R an in-depth psychi-
atric questionnaire which gives an ICD-10 diagnosis.
Participants will be asked for details of their prescribed
medication, prior use of antidepressants and whether
they are currently in receipt of psychological therapy.
In addition, socio-demographic details will be recorded
(age, gender, ethnicity, marital status), together with
information on a number of socio-economic markers
(employment status, housing situation).
Potential participants who score 14 or more on the
BDI-II, and who have an ICD-10 primary diagnosis of
depression using the CIS-R, will be told they are poten-
tially eligible to enter the trial (pending confirmation by
the principal investigator (PI)) and will be asked to pro-
vide further written consent for trial participation, and
to indicate whether they would be willing to be con-
tacted about future research projects.
These potentially eligible participants will also be asked
to complete some further questionnaires including: the
General Anxiety Disorder questionnaire (GAD-7) [28];
EQ-5D-5 L [29], a brief measure of health-related quality
of life; SF-12, a brief measure of mental and physical func-
tioning; ASEC measure of antidepressant side effects [30].
They will be asked further questions about their history of
depression and whether they have ever been referred to a
psychiatrist; and about the strength of their preference for
active treatment over placebo (as this may potentially
affect medication adherence and outcomes). Additional
information will be collected on life events, financial
stress, social support and alcohol use [31].
Once the baseline assessment is complete, the local
research clinician (PI) will review the baseline informa-
tion and confirm whether the patient is eligible for the
MIR trial.
Randomisation procedure and code break (unblinding)
Following the baseline assessment, eligible and consent-
ing participants will be randomised using the automated
randomisation service provided by Bristol Randomised
Trials Collaboration. Randomisation will be by means
of a computer-generated code to ensure concealment
of allocation.
Participants are randomly assigned to one of two
treatments: (1) one × 15 mg encapsulated mirtazapine
daily for 2 weeks followed by two × 15 mg encapsulated
mirtazapine for up to 50 weeks; or (2) identical placebo.
Randomisation will be stratified by centre (n = 4) to
ensure a balance in terms of local differences. Mini-
misation will be used to ensure balance in baseline
BDI-II score (using approximate tertiles derived from
the CoBalT baseline scores; <26; 26–34, ≥35), gender
and whether the patient is currently receiving a
psychological therapy; ensuring a balance in these im-
portant prognostic indicators. We will use minimisa-
tion with a probability weighting of 0.8 in order to
reduce predictability [32].
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Patient packs containing the trial medication will be
sent to the participant’s GP (or home in exceptional
circumstances) at regular 6–8 week intervals.
Participants are free to withdraw from the medication
at any time. Patients, clinicians, outcome assessors, data
analysts and the rest of the research team will be blinded
to allocation. All patients continue with their GP care
and usual antidepressant as agreed by their GP. Clini-
cians will not be restricted in their use of psychological
services.
Unblinding will be available via the trial pharmacy at
all times in case of a medical emergency (‘emergency
unblinding’). After the 12-week primary outcome has
been completed, the code can also be broken at the re-
quest of the participant or their GP (‘routine unblinding’).
Those who have not requested emergency or routine
unblinding, will be unblinded at the end of the follow-up
period, or on withdrawal from the study. The trial team
will not provide further supplies of the trial medication
once participants have been unblinded.
Follow-up schedule
At 2 weeks post - baseline, researchers will contact par-
ticipants briefly by telephone to check they have received
and started their trial medication.
At 6, 12, 24 and 52 weeks, participants will be asked
to complete self-report outcome questionnaires. The
follow-up schedule is summarised in the flow-chart
(Fig. 1) and table (Table 2). Follow-up questionnaires
can be completed face-to-face with the researcher, by
phone, or by post. If a postal questionnaire is not returned,
a reminder will be sent.
Throughout the follow-up process participants are
asked about possible adverse effects and advised to con-
sult their GP about these if appropriate. Participants
will be sent a £5 gift voucher with each of the 12-week,
Fig. 1 Summary of the follow-up schedule – flow-chart illustrating the follow-up schedule for the MIR study
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24-week, and 12-month questionnaires, to thank them
for their participation.
At the end of the 12-month follow-up period, (or on
withdrawal from the study), participants will be advised
to return to their GP to discuss their continued care.
Withdrawal of trial participants
Participants can withdraw from the trial at any time for
any reason, without their medical care being affected.
Where possible, data already collected will continue to
be used in the trial and patients who withdraw from the
trial will be asked if they are still willing to provide
follow-up data. If a patient withdraws, the reason for,
and type of, withdrawal will be documented in the Case
Report Form (CRF).
PIs have the right to withdraw patients from the trial
drug in the event of inter-current illness, Adverse Events
(AEs), Serious Adverse Events (SAEs), Suspected Unex-
pected Serious Adverse Reactions (SUSARs), protocol
violations, administrative reasons or other reasons; this
will be documented in the CRF.
Although there is no evidence that the medication is
teratogenic, if a patient discovers that she is pregnant
during the trial she will be instructed to stop her trial
medications immediately, though she will be able to con-
tinue to participate in completion of the trial outcome
measures if she wishes. A longer monitoring period will
be put in place to establish the safe delivery of a healthy
infant, at which point follow-up will stop.
Outcome measures
Primary outcomes:
Continuous BDI-II score at 12 weeks, adjusting for
baseline.
Secondary outcomes:
1. Treatment response, measured as an improvement
of at least 50 % in BDI-II score at 12 weeks
compared with baseline
2. The rate of remission of symptoms, defined as a
score on the BDI-II of less than 10 at 12 weeks
3. Change in anxiety symptoms (measured with
GAD-7) at 12 weeks
4. All of the above outcomes at 24 weeks and
12 months
5. Antidepressant use and adherence
(using Morisky and additional questions)
6. Quality of life (using the EQ-5D-5L) and
social and physical functioning (SF-12),
at 12 weeks, 24 weeks and 12 months
7. Adverse Events including: any new symptoms or
worsening of existing symptoms, consultations for a
documented deterioration in illness and Serious
Adverse Events (self-reported, or from primary care
Table 2 Full schedule of questionnaires – table showing the questionnaires scheduled for the MIR study
Questionnaire Postal screening Baseline 2 weeks call 6 weeks 12 weeks 24 weeks 12 months
Consent form Y
BDI-II Y Y Y Y Y Y
Biographic and demographic data including
psychiatric history, life events, social support, alcohol use
Y Y
Views on treatment Y
Assessment of blinding Y
Medication Y Y Y Y Y Y
Morisky (adapted) Y Y Y Y Y Y
CIS-R Y
PHQ9 Y Y Y Y
GAD-7 Y Y Y Y
EQ-5D-5L Y Y Y Y
SF-12 Y Y Y Y
Economics Y Y Y
Health events (SAEs) Y Y Y Y
ASEC Y Y Y
2-week check Y
Blinding questions Y
Exit questionnaire Y
ASEC Antidepressant Side Effect Checklist, BDI-II Beck Depression Inventory II, CIS-R Clinical Interview Schedule-Revised version, EQ-5D-5L EuroQol 5 dimensions 5
levels quality of life questionnaire, GAD-7 Generalised Anxiety Disorder-7 questionnaire, PHQ9 Patient Health Questionnaire, SAE Serious Adverse Event, SF-12 social
and physical functioning questionnaire short form 12
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notes review); adverse effects (using the
Antidepressant Side Effect Checklist (ASEC) [30]
at 12 weeks and 12 months)
8. Cost-effectiveness from the perspectives of the
NHS, patients, and society (using self-report
questionnaires at 12 and 24 weeks, and at 12 months;
and primary care practice data on consultations,
services and prescriptions over the 12-month
trial period)
Trial medication
The active trial drug will be mirtazapine: 1 × 15 mg oral
capsule per day for 2 weeks followed by 2 × 15 mg oral
capsules per day for up to 12 months. The mirtazapine
will be encapsulated and the placebo will be an identical
capsule filled with an inert excipient. The placebo cap-
sule will exactly match the encapsulated mirtazapine in
dimensions and appearance, so that allocation conceal-
ment and blinding of the trial is maintained.
Packaging, labelling and dispensing
The labelling of medication packs will be Medicines and
Healthcare products Regulatory Authority (MHRA) ap-
proved and conform to Annexe 13 of Good Manufac-
turing Practice (GMP) standards and Article 13.3 of
Directive 2001/20/EC [33]. Each medication pack will
have a medicine identification number, randomly gener-
ated to ensure mirtazapine and placebo medicine packs
are indistinguishable and thus maintain allocation con-
cealment. This random number will be generated by
the Bristol Randomised Trials Collaboration and pro-
vided to the manufacturer who will use it to form the
identifier.
Sharp Clinical Services will provide Qualified Person
(QP) services and distribution and project management.
They will ship labelled and numbered packages to the
central trial pharmacy (University Hospitals Bristol
(UHB) Clinical Trials Pharmacy), where the trial medica-
tion will be stored under controlled conditions. Storage
will be secure, and there will be a delegation log for access,
for which the trial pharmacy will take responsibility. The
trial pharmacy will dispense individual patient packs and
oversee the packaging and posting of those packs. Patient
packs containing no more than an 8-week supply of the
trial medication will be posted by recorded delivery. All
deliveries will be logged to ensure drug accountability.
The trial medication will be shipped and stored in
conditions in line with manufacturer’s stability data.
Concomitant medication
Pharmacodynamic interactions:
Mirtazapine should not be administered concomitantly
with MAO inhibitors or within 2 weeks after discontinu-
ation of MAO inhibitor therapy. Likewise about 2 weeks
should pass before patients treated with mirtazapine
should be treated with MAO inhibitors. Participants in
this study will not be treated with MAO inhibitors and
GPs will be advised to wait at least 2 weeks after stop-
ping the trial medication before starting an MAO
inhibitor.
Co-administration with other serotonergic active sub-
stances (L-tryptophan, triptans, tramadol, linezolid,
lithium and St. John’s Wort – Hypericum perforatum –
preparations) may lead to an incidence of serotonin-
associated effects and participants will be advised to
use these medications with caution. Mirtazapine may
increase the sedating properties of benzodiazepines and
other sedatives (notably most antipsychotic drugs, anti-
histamine H1 antagonists, opioids). Caution should be
exercised when these medicinal products are prescribed
together with mirtazapine.
Mirtazapine may increase the central nervous system
depressant effect of alcohol. Participants will, therefore,
be advised to be cautious in their intake of alcohol while
taking mirtazapine.
Other concomitant care (including switching, dis-
continuing, or changing the dose of SSRI/SNRI medi-
cation, and receipt of psychological therapies) will not
be prohibited.
Adverse Events (AEs)
All AEs (untoward medical occurrences affecting trial
participants) will be recorded in the CRF for the dur-
ation of the participant’s direct involvement in the trial
(12 months). For all events recorded, Centre PIs will rec-
ord their opinion concerning the nature and severity of
the AE, and its relationship to trial therapy.
All SAEs must be reported to UHB (which monitor
SAEs on behalf of the sponsor) and the Centre PI by
the research team within 24 hours of their knowledge
of the event. The chief investigator (CI) and trial man-
ager will also be informed. All SAEs that have not
resolved by the end of the trial (that is, by the end of
the primary care notes review follow-up period), or that
have not resolved upon discontinuation of the partici-
pant’s participation in the trial, must be followed until:
the event resolves/stabilises/returns to baseline/can be
attributed to other factors unrelated to the trial; or it
becomes unlikely that additional information can be
obtained.
All relevant information about a Suspected Unexpected
Adverse Reaction (SUSAR) that occurs during the course
of the trial will be reported to the MHRA and the relevant
ethics committee by UHB, on behalf of the sponsor as
soon as possible (fatal or life-threatening SUSARs will be
reported within 7 days, and those which are not fatal or
life-threatening within 15 days).
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The expectedness of an AE will be determined by
whether or not it is listed in the Summary of Product
Characteristics, the BNF and study protocol.
Trial stopping rules
The trial may be prematurely discontinued by the
sponsor, CI, regulatory authority or funder on the basis
of new safety information or for other reasons given by
the Data Monitoring Committee (DMC)/Trial Steering
Committee (TSC) regulatory authority or ethics com-
mittee concerned.
The trial may also be prematurely discontinued due to
lack of recruitment or upon advice from the TSC, which
will advise on whether to continue or discontinue the
trial and make a recommendation to the sponsor. If the
trial is prematurely discontinued, active participants
will be informed and no further participant data will be
collected.
Statistical analysis
Analysis and reporting will be in line with Consolidated
Standards of Reporting Trials (CONSORT) guidelines
[34], with the primary analyses being conducted on an
intention-to-treat (ITT) basis. Descriptive statistics will
be used to ascertain any marked imbalances in demo-
graphic or clinical variables at baseline.
The primary analysis will be the BDI-II score at 12 weeks
post randomisation, measured as a continuous variable.
The primary analysis will use linear regression to compare
the groups as randomised, adjusting for stratification and
minimisation variables and baseline measurements of the
outcome. Secondary analyses of this outcome will include
the BDI-II score at 12 weeks post randomisation as a
binary variable representing response, defined as a reduc-
tion in depressive symptoms of at least 50 % compared to
baseline, and remission, defined as a BDI-II score of less
than 10. Secondary analyses will also include additional
adjustment for any prognostic variables demonstrating
marked imbalance at baseline.
We will conduct pre-planned subgroup analyses to
investigate any differential effects according to a num-
ber of factors. These will be done by introducing
appropriate interaction terms in the regression models.
We will carry out these analyses by baseline depression
severity (BDI-II) and a five-level measure of the degree
of treatment resistance based on duration of symptoms
and prior treatment with antidepressants.
In all analyses we will present regression coefficients
(or odds ratios for binary outcomes), with 95 % confi-
dence intervals and p values.
We will also use repeated measures analyses incorpor-
ating the outcomes at 12 and 24 weeks and 12 months
post randomisation to examine whether any treatment
effects are sustained, diminished or emerge later. This
will be investigated formally by the introduction of an
interaction between treatment group and time. Finally,
we will also investigate the influence of missing data
using sensitivity analyses that make different assump-
tions, such as ‘best’ and ‘worst’ case scenarios, as well as
using models to impute missing data [35, 36].
We propose to carry out per protocol analyses at
12 weeks and 12 months comparing individuals who
have remained on the trial medication at that follow-up
point. Since these analyses are likely to be biased, we will
also use the Complier Average Causal Effect (CACE)
[37] approach. This provides an unbiased estimate of the
treatment effect for those who have complied with the
active treatment. This approach would be justified if the
characteristics of those who adhered to the placebo dif-
fered from those who adhered to mirtazapine. This is
plausible as we would expect intolerance of the side ef-
fects to be more important for the mirtazapine group
and non-response to be more of an issue for the placebo
group. If there is differential adherence in the two arms
we will also investigate structural mean approaches to
take account of this [38] though extensions of CACE to
take account of adherence to placebo have also been de-
veloped [39].
At 12 and 24 weeks and 12 months, the ITT analysis
will compare the randomised groups. By these stages, we
would still expect many of those who had responded to
mirtazapine to remain on the combination treatment.
The ITT analysis will, therefore, provide an estimate of
any longer-term benefit attributed to the early response
to mirtazapine with an SSRI/SNRI. The interpretation of
this will depend upon whether other potentially active
interventions are balanced between the groups. We do
not expect to see many marked imbalances in other
treatments, as our previous trials (IPCRESS [40], CoBalT
[18]) have not found this to be a problem. If we do find
that the groups differ markedly in the two arms we will
investigate any possible impact of this by adjustment for
the other interventions in the regression model.
A further sensitivity analysis using CACE methods will
be used at 24 weeks and 12 months. If we define
‘compliers’ as those who had continued taking their trial
medication up until 12 weeks, we could then estimate
the effect of completing a 12 week course of mirtazapine
on depression outcomes at the later follow-up points
(24 weeks and 12 months).
Justification of sample size
The primary outcome is BDI-II score as a continuous
variable. It is difficult to estimate a clinically important
difference in BDI-II score, although the NICE guideline
panel for the first depression guideline [4] suggested that
this corresponds to about 3 points (0.35 standard devia-
tions) on the Hamilton Depression Rating Scale (HDRS)
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[41] for non-treatment-resistant patients, and 2 points
for those who are treatment-resistant. The equivalent
difference to 3 HDRS points on the BDI-II total score
would be 3—4 points (standard deviation 10—12 in the
CoBalT trial). With 200 participants in each group, we
would have 91 % power to detect a difference of 0.33
standard deviations at the 5 % level. Allowing for 15 %
loss to follow-up at 12 weeks, we will need to recruit
472 patients.
For our secondary outcome, response rate, defined as
a 50 % reduction in symptoms using the BDI-II score,
200 patients in each group would yield 90 % power to
detect a difference between 30 and 46 % response, or an
odds ratio of 2, at a two-sided 5 % significance level.
We therefore aim to recruit 120 patients from 24
general practices at each of the four recruiting centres
(Bristol, Exeter, Keele and Hull).
Blinding and other forms of bias
Participants, GPs and investigators will be blinded to
treatment. The effectiveness of blinding will be assessed
by a brief questionnaire asking participants to which
arm they believed they had been allocated at the 12-
week follow-up.
Economic evaluation
The economic evaluation will assess the efficiency of
mirtazapine plus SSRI or SNRI compared with SSRI or
SNRI alone, for primary care patients with TRD. Re-
source use data will be collected from general practice
records review (e.g. number of consultations, prescribed
medications and referrals) and a resource use question-
naire (e.g. other community based care, outpatient and
inpatient care), completed by participants at 12 and
24 weeks and 12 months. The questionnaire also collects
information on employment, time off work, disability
payments, informal help, and patient expenditure on
healthcare. Publicly available national unit costs will be
used to value prescribed medications [17], primary and
community care consultations, social services [42] and
secondary care [43]. Patients’ time off work and informal
help from family and friends will be valued using the
human capital approach; we will explore the robustness
of our conclusions to other methods for valuing lost
productivity [44].
In the primary economic analysis we will estimate the
incremental net monetary benefit (iNMB) [45] of
combined therapy with mirtazapine at 12 weeks from
the perspective of the NHS and social services.
The 12-week time point is selected as clinicians and
patients will be blind to treatment allocation. The iNMB
estimates whether any additional costs of mirtazapine
are justified by improved outcomes (Quality-adjusted
Life Years (QALYs)) for patients at conventional thresholds
used by NICE (i.e. £20,000 and £30,000 per QALY) [46].
QALYs will be estimated from responses to the EQ-5D-5L
controlling for baseline responses [47]. In secondary ana-
lyses we will report the iNMB over the 52-week follow-up
period and the incremental cost per responder, based on
BDI-II, at 12 and 52 weeks. For each analysis, stochastic
uncertainty in results will be estimated using confidence
intervals and cost-effectiveness acceptability curves. Other
uncertainty will be addressed in deterministic sensitivity
analyses; specifically, we will explore whether our conclu-
sions are sensitive to the inclusion of patient and wider
societal (i.e. lost productivity) costs.
Qualitative study
A nested qualitative study will: (1) explore patients’
views and experiences of taking either two antidepres-
sant medications or an antidepressant and a placebo; (2)
identify patients’ reasons for completing or not completing
the study, including withdrawal from study medication;
and (3) explore the views of GPs on prescribing a second
antidepressant in this patient group.
At the baseline assessment for the main study, individ-
uals will be informed about the qualitative study and be
asked to consent to the possibility of being contacted by
the qualitative research team to take part in an inter-
view. A purposeful sampling strategy will be used to
identify potential interviewees to ensure interviews are
held with participants in both arms of the trial, and with
individuals in both arms who vary in their levels of
adherence. Maximum variation sampling techniques will
be used so that patients of different socio-economic
background, gender and age are invited for interview.
Patients will be sampled across the four centres.
A purposive sample of trial participants will be invited
to participate in a semi-structured interview, and per-
spectives on taking two tablets for depression will be ex-
plored. Patients who took the trial medication for at
least 12 weeks, and those who stopped, will be sampled.
Interviews will be conducted either face to face or by
telephone. The interviews will be taped with consent,
transcribed, and the transcripts will form the data for
analysis. It is anticipated that at least 24 interviews will
be needed to achieve category saturation. Interviews will
be held with patients after the primary outcome measure
has been obtained (at 12 weeks post randomisation) to
avoid the possibility of bias that might be introduced by
the qualitative interview having a supportive role.
Individuals will be interviewed within 8 weeks of their
primary outcome measures being taken.
In addition, patients who decline to participate in the
trial will be asked if they would be willing to be con-
tacted by a researcher to discuss their reasons for not
taking part. Using short semi-structured telephone inter-
views, their views on the trial, and perspectives on taking
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two tablets for depression will be explored. The inter-
views will last 10—30 minutes and will be taped with
consent, transcribed, and transcripts analysed. It is antic-
ipated that at least 15 interviews will be needed.
Finally, a purposive sample of GPs (sampled on the
basis of practice demographics and size, experience and
status (partner, salaried, locum) participating in the trial
will be invited to participate in a semi-structured inter-
view which will be taped (with consent). The interviews
will be conducted either face to face or by telephone.
Interviews will explore perspectives and views of GPs
about managing people with depression, use of antide-
pressants and talking treatments, alternative approaches,
switching antidepressants and referral options. The role
of national guidelines (particularly about prescribing) in
guiding individual management of a patient with depres-
sion will be explored. The interviews with be transcribed
and the transcripts forming the data for analysis. It is
anticipated that between 16 and 20 interviews will be
needed to achieve category saturation of the data.
Trial participants and GPs will be interviewed at a
time and place that is convenient for them (such as their
home, GP surgery or by telephone). Written consent to
take part in an interview will be obtained from partici-
pants and GPs at the time of face-to-face interviews, or
prior to telephone interviews. These interviews will last
about an hour. With participant consent, they will be
audio-recorded and transcribed verbatim.
Data will be coded by two researchers independently.
Thematic analysis will identify and categorise relevant
and recurrent concepts within the data set, guided by
the research questions of the study. Thematic analysis
is guided by a priori concepts but also allows for quali-
tative data sets to be interrogated in an inductive man-
ner. Themes are produced which unify the conceptual
categories [48]. Both data sets will be interrogated and
re-analysed against the Normalisation Process Theory
framework [49] in order to consider how prescribing
two antidepressants may, or may not, be normalised
into clinical practice.
Quality assurance
The trial sponsor takes primary responsibility for ensuring
that the design of the study meets appropriate standards
and that arrangements are in place to ensure appropriate
conduct and reporting. The trial will be run in accordance
with Good Clinical Practice (GCP) and current regulatory
guidance.
We will employ standard strategies to ensure the qual-
ity of the data; for example, a random sample of 20 % of
CRFs will be checked, by the trial research team, against
entries within the database. Recruiting sites will be asked
to perform a self-audit on all entries and provide a re-
turn to the Bristol trial centre (who will report to the
trial sponsor). A 10 % sample audit will be conducted by
the UHB monitoring team.
Data handling
The database and randomisation system will be designed
so as to protect patient information and maintain ano-
nymity. Data will be securely stored in line with the Data
Protection Act 1998. The CI is the custodian of the data.
Access to the final data set will be restricted to the MIR
study team in the first instance. The team will be open to
requests by other investigators to access anonymised data.
Publication policy
An MIR publication policy will be developed and trial
publications will be subjected to an independent quality
assurance procedure. Publications will conform to the
International Committee of International Journal Editors
(ICMJE) guidelines for reporting and authorship [50].
Ethics and regulatory approvals and reporting
The trial will be conducted in compliance all applicable
regulatory requirements.
Substantial protocol amendments will be submitted to
the Research Ethics Committee (REC) and MHRA, on
the agreement of the sponsor. Protocol changes will be
disseminated to recruiting sites and GP collaborators as
appropriate.
Progress reports will be submitted to the REC and
funder as required and will be made available to the DMC
and TSC as appropriate. These groups act independently
of the investigators and sponsor; further details of these
committees are available on request. Annual safety reports
will be sent to the MHRA and the REC. An end of study
declaration will be submitted to the REC and MHRA. A
final report at conclusion of the trial will be submitted to
the NIHR, the sponsor, the REC and the MHRA within
1 year of the end of the trial. A summary of the overall
trial results will be made available to those participants
who have confirmed that they wish to receive them, and
to GPs who have recruited to the study.
Insurance indemnity
The University of Bristol holds professional negligence
insurance to cover the legal liability of the university,
for harm to participants arising from the design of the
research, where the research protocol was designed by
the university. The University of Bristol has arranged
public liability insurance to cover the legal liability of
the University as Research Sponsor in the eventuality of
harm to a research participant arising from overall
management of the research by the University of Bristol.
The other three recruiting sites (Keele, Exeter, Hull) have
their own public liability insurance in place for their
individual responsibilities.
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Discussion
At this stage of the trial, we anticipate there may be
methodological weaknesses in the design, such as inad-
vertent unblinding due to the common adverse effects of
mirtazapine. However, we will address this by asking
participants which treatment arm they thought they
were allocated, and including this data in the analysis.
The trial has a number of strengths. MIR is a prag-
matic primary care study, which will recruit partici-
pants from a wide range of primary care practices
across the UK. It will also be the largest UK study of
two combined antidepressants. We have also included a
longer (12-month) follow-up period to reflect the
chronicity of the condition. In addition, the qualitative
study will tell us more about the acceptability of the
intervention to both doctors and patients.
It is important that large pragmatic trials of pharmaco-
logical interventions for depression have a placebo arm,
since the mean placebo response in treatment trials of
major depression has been found to be close to 30 %
[51]. We have also used self-report instruments to assess
outcomes in order to eliminate the potential for observer
bias. Selection bias will be minimised by recruiting
participants from a variety of practices based in rural,
urban, affluent and deprived areas across the four cen-
tres. Exclusion criteria are minimal. These strengths
will make the findings more generalisable.
There is substantial unmet clinical need in this popu-
lation. The intervention is simple, and is likely to be
taken-up in primary care if found to be effective and not
associated with an unacceptable level of adverse effects
such as weight gain in longer-term use. The evidence
from the trial will make a contribution to rational and
cost-effective prescribing in this important area of
patient need, where it is known that current treatments
are only partly effective. We think there may be a real
opportunity to substantially improve the treatment of
depression by combining antidepressants with comple-
mentary modes of action. This strategy is only rarely
used in primary care at present.
Trial status
The study began recruiting participants in August 2013
and will be ongoing until the end of September 2015. At
the time of writing (August 2015), 106 GP practices have
agreed to collaborate with MIR, and 431 participants
have been recruited. It is anticipated that data collection
will be completed in October 2016 and results will be
available in May 2017.
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